As of 29 September 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of bevacizumab [25 mg/mL concentrate for solution for intravenous (IV) infusion] in combination with a platinum-taxane doublet chemotherapy, specifically cisplatin [1 mg/mL solution for IV infusion] or carboplatin [10 mg/mL solution for IV infusion; lyophilized powder continue reading : HTA Council Preliminary Recommendation on bevacizumab [25 mg/mL concentrate for solution for intravenous (IV) infusion] in combination with a platinum-taxane doublet chemotherapy, specifically cisplatin [1 mg/mL solution for IV infusion] or carboplatin [10 mg/mL solution for IV infusion; lyophilized powder for injection in 150 mg and 450 mg vial] + paclitaxel [6 mg/mL solution for IV infusion] for the treatment of metastatic, persistent or recurrent cervical cancer
HTA Council Final Recommendation on citicoline for adult patients with ischemic stroke
Date of submission of the HTAC Recommendation: 18 October 2024Date of notification to HTAC on the SOH decision: 24 September 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on citicoline for adult patients with ischemic stroke through Department of Health (DOH) Department Circular No. 2026-0531 “Non-Inclusion of Citicoline continue reading : HTA Council Final Recommendation on citicoline for adult patients with ischemic stroke
HTA Council Preliminary Recommendation on alendronic acid (as sodium alendronate) 70 mg effervescent tablet for the treatment of postmenopausal osteoporosis
As of 24 September 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of alendronic acid (as sodium alendronate) 70 mg effervescent tablet for the treatment of postmenopausal osteoporosis. The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from 24 continue reading : HTA Council Preliminary Recommendation on alendronic acid (as sodium alendronate) 70 mg effervescent tablet for the treatment of postmenopausal osteoporosis
HTA Council Final Recommendation on abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC)
Date of submission of the HTAC Recommendation: 10 August 2026Date of notification to HTAC on the SOH decision: 15 September 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC) through Department continue reading : HTA Council Final Recommendation on abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC)
HTA Council Final Recommendation on levothyroxine sodium 12.5 micrograms (mcg) and 25 mcg tablets for the management of hypothyroidism of any etiology
Date of submission of the HTAC Recommendation: 20 July 2026Date of notification to HTAC on the SOH decision: 26 August 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on levothyroxine sodium 12.5 micrograms (mcg) and 25 mcg tablets for the management of hypothyroidism of any etiology through Department continue reading : HTA Council Final Recommendation on levothyroxine sodium 12.5 micrograms (mcg) and 25 mcg tablets for the management of hypothyroidism of any etiology